The Delphi methodology was used to assess experts’ opinions on the available literature related to lymphedema, to provide consensus guidance on diagnosis and patient treatment pathways for this commonly overlooked condition. Experts from the
- Cancer, infection, chronic venous disease, and surgery are all risk factors for secondary lymphedema.
- Patients with CVI, clinical stages 3-6, should be treated as lymphedema patients.
- Clinical examination is sufficient for the diagnosis of lymphedema.
- Regular use of compression garments reduces progression of lymphedema.
- 92% of the panel agreed that sequential pneumatic compression should be recommended for lymphedema patients.
“Recommended use of pneumatic compression achieved the highest level of consensus, and it is encouraging to see such uniformity among three independent professional societies,” said
The publication in Phlebology:
About Tactile Medical
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “continue,” “confident,” “outlook,” “guidance,” “project,” “goals,” “look forward,” “poised,” “designed,” “plan,” “return,” “focused,” “prospects” or “remain” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company’s control that can make such statements untrue, including, but not limited to, the impacts of the COVID-19 pandemic on the Company’s business, financial condition and results of operations and the Company’s inability to mitigate such impacts; the adequacy of the Company’s liquidity to pursue its business objectives; the Company’s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives, including prior to identifying a successor; adverse economic conditions or intense competition; loss of a key supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; price increases for supplies and components; the effects of current and future
Mike Piccinino, CFA ICR Westwicke 443-213-0500 [email protected]
Source: Tactile Systems Technology, Inc.